LEADER 04707nam 22007335 450 001 9910437996003321 005 20250711081756.0 010 $a1-283-93413-2 010 $a1-4614-5456-5 024 7 $a10.1007/978-1-4614-5456-4 035 $a(CKB)2670000000316161 035 $a(EBL)1081925 035 $a(OCoLC)823388516 035 $a(SSID)ssj0000878460 035 $a(PQKBManifestationID)11560734 035 $a(PQKBTitleCode)TC0000878460 035 $a(PQKBWorkID)10815014 035 $a(PQKB)10546703 035 $a(DE-He213)978-1-4614-5456-4 035 $a(MiAaPQ)EBC1081925 035 $a(PPN)168303086 035 $a(EXLCZ)992670000000316161 100 $a20121212d2013 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntibody-Drug Conjugates and Immunotoxins $eFrom Pre-Clinical Development to Therapeutic Applications /$fedited by Gail Lewis Phillips 205 $a1st ed. 2013. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Humana,$d2013. 215 $a1 online resource (369 p.) 225 1 $aCancer Drug Discovery and Development,$x2196-9914 300 $aDescription based upon print version of record. 311 08$a1-4899-9700-8 311 08$a1-4614-5455-7 320 $aIncludes bibliographical references and index. 327 $aAntibody Directed Delivery for Treatment of Cancer: Antibody Drug Conjugates and Immunotoxins -- Antibody-Drug Conjugate Development -- Components of ADC Development: Assay Methodologies and Challenges -- Clinical Pharmacology Strategies in the Development of Antibody-Drug Conjugates -- Predictive Biomarkers for Antibody-Drug Conjugates -- Factors Involved in the Design of Cytotoxic Payloads for Antibody-Drug Conjugates -- Linker Technology and Impact of Linker Design on ADC Properties -- Antibody-drug conjugates for the treatment of B-cell malignancies -- Targeting CD19 with SAR3419, an anti-CD19-Maytansinoid Conjugate for the Treatment of B Cell Malignancies -- Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies -- Trastuzumab Emtansine (T-DM1) for the Treatment of HER2-Positive Cancer -- CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE) -- Case Study: An Antibody-Drug Conjugate Targeting MUC16 for Ovarian Cancer -- EphA2 Immunoconjugate -- Anti-PSMA Antibody-Drug Conjugates -- Targeting CD56 (NCAM)-expressing Neoplasms with Lorvotuzumab Mertansine -- Studies on the Metabolism of Antibody-Drug Conjugates -- Design, Development and Characterization of Recombinant Immunotoxins Targeting HER2/neu -- The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors -- Index. 330 $aThe concept of delivering ?magic bullets? to treat diseases was first proposed by Paul Erlich in the early 1900?s.  The realization of this concept for the treatment of cancer occurred in the late 1990?s with the approval of monoclonal antibody therapies.  The use of monoclonal antibodies conjugated (linked) to potent cytotoxic agents (antibody-drug conjugates, ADCs) for specifically delivering cytotoxics to cancer cells was an obvious extension of antibody-based therapy.  ADCs have been under intense investigation for several decades; progress, however, has been limited due to toxicity or lack of improved efficacy compared to unconjugated cytotoxics.  More recently, linker technology and target selection have advanced such that several ADCs and immunotoxins are undergoing clinical testing or are approved for use.  This important volume gives the latest and most comprehensive information on the topic, describing different types of ADCs and immunotoxins for both hematologicand solid malignancies. Finally, the volume highlights the promise that this technology holds for diverse types of human cancer. 410 0$aCancer Drug Discovery and Development,$x2196-9914 606 $aCancer 606 $aMedicine$xResearch 606 $aBiology$xResearch 606 $aImmunospecificity 606 $aCancer Biology 606 $aBiomedical Research 606 $aAdaptive Immunity 615 0$aCancer. 615 0$aMedicine$xResearch. 615 0$aBiology$xResearch. 615 0$aImmunospecificity. 615 14$aCancer Biology. 615 24$aBiomedical Research. 615 24$aAdaptive Immunity. 676 $a615.37 676 $a615.373 701 $aPhillips$b Gail Lewis$01762253 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910437996003321 996 $aAntibody-drug conjugates and immunotoxins$94202046 997 $aUNINA